Introduction：Basic information about FILGRASTIM CAS 121181-53-1, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
FILGRASTIM Basic information
| Product Name: | FILGRASTIM |
| Synonyms: | FILGRASTIM;n-l-methionyl-colony-stimulatingfactor(humanclone1034;Colony-stiMulating factor (huMan clone 1034), N-L-Methionyl- (9CI);Filgrastim CRS;FILGRASTIM USP/EP/BP;FilgrastimDISCONTINUED;Figrastim;filgrastimconcentratedSolution |
| CAS: | 121181-53-1 |
| MF: | W99 |
| MW: | 0 |
| EINECS: | |
| Product Categories: | |
| Mol File: | Mol File |
|
FILGRASTIM Chemical Properties
| storage temp. | -70°C |
| Major Application | pharmaceutical (small molecule) |
Safety Information
| WGK Germany | WGK 3 |
| HS Code | 3002905150 |
| Storage Class | 11 - Combustible Solids |
| Hazardous Substances Data | 121181-53-1(Hazardous Substances Data) |
| Toxicity | LD50 oral in rat: > 3mg/kg |
FILGRASTIM Usage And Synthesis
| Description | Filgrastim is a recombinant human granulocyte colony stimulating factor (G-CSF)indicated as an adjunct to cancer chemotherapy for patients with non-myeloidmalignancies. It reduces the duration of chemotherapy-induced neutropenia by forcingimmature leucocytes to differentiate into neutrophils, thereby decreasing the incidenceand length of infections.Bone pain is the most significant side effect.Chugailaunched the second G-CSF, lenograstim, in December 1991. Other potential usesinclude bone marrow transplants, myelodysplastic syndromes and febrilelchronicneutropenia. |
| Chemical Properties | Clear, colourless or slightly yellowish liquid |
| Originator | Amgen (U.S.A.) |
| Uses | Antineutropenic; hematopoietic stimulant. |
| Uses | Filgrastim is a human granulocyte colony stimulating factor (G-CSF) used to treat neutropenia. |
| Indications | Filgrastim (Neupogen) is a human recombinant granulocytecolony–stimulating factor (rG-CSF) producedusing recombinant DNA technology. It acts on precursorhematopoietic cells in the bone marrow by bindingto specific receptors that stimulate cellular proliferationand differentiation into neutrophils. It also enhancessome neutrophil functions, including phagocytosis andantibody-dependent killing. |
| Brand name | Neupogen (Amgen). |
| Clinical Use | Filgrastim, G-CSF, Neupogen, stimulates the proliferation ofgranulocytes (especially neutrophils) by mobilizinghematopoietic stem cells in the bone marrow. The native protein is glycosylated.Filgrastim selectively stimulates proliferation and differentiationof neutrophil precursors in the bone marrow. Thisleads to the release of mature neutrophils into the circulationfrom the bone marrow. Filgrastim also affects mature neutrophilsby enhancing phagocytic activity, priming the cellularmetabolic pathways associated with the respiratoryburst, enhancing antibody-dependent killing, and increasingthe expression of some functions associated with cell surfaceantigens.
In patients receiving chemotherapy with drugs such ascyclophosphamide, doxorubicin, and etoposide, the incidenceof neutropenia accompanied by fever is rather high.Administration of G-CSF reduces the time of neutrophilrecovery and duration of fever in adults with acute myelogenousleukemia. The number of infections, days thatantibiotics are required, and duration of hospitalization arealso reduced. |
| Clinical Use | Filgrastim is used to accelerate recovery of neutrophilsafter chemotherapy, both to prevent infectionsand to shorten the duration of neutropenia in patientsin whom infections have developed. |
| Side effects | The drug is generally well tolerated, with the majoradverse reaction being mild to moderate bone pain secondaryto stimulation of bone marrow proliferation. |
| Veterinary Drugs and Treatments | Filgrastim may be of benefit in treating neutropenias in dogs orcats when the intrinsic response to endogenously produced cytokinesis thought to be inadequate and there is evidencethat there areprecursors in the bone marrow available. Because of the drug’s costand lack of good evidence for its efficacy in reducing mortality versususing antibiotic therapy alone, its use in small animal medicineis somewhat controversial. |
| Drug interactions | Potentially hazardous interactions with other drugs Cytotoxics: neutropenia possibly exacerbated with capecitabine, fluorouracil and tegafur. |
| Metabolism | Filgrastim is primarily eliminated by the kidney and neutrophils/neutrophil precursors; the latter presumably involves binding of the growth factor to the G-CSF receptor on the cell surface, internalisation of the growth factor-receptor complexes via endocytosis, and subsequent degradation inside the cells |
FILGRASTIM Preparation Products And Raw materials
